Balanced product information
Evidence, limitations and safety — in one consistent format.
This page separates authorised uses from investigational or reported uses. It does not provide personal medical advice or dosing instructions.
Product name
GHK-Cu, BPC-157 and TB-500 injectable peptide blend (Glow Skin)
Catalogue label details describe what is displayed; they do not independently verify composition, quality, batch release or UK marketing authorisation.
What is it?
Glow Skin is a catalogue name for an injectable blend containing the copper-binding peptide GHK-Cu with BPC-157 and TB-500.
GHK-Cu has been studied mainly in laboratory, wound and topical cosmetic contexts. BPC-157 and TB-500 are experimental peptides; the exact 112mg injected combination is not an established medicine.
Intended / recognised uses
Authorised / recognised uses
- There are no authorised UK medical or cosmetic uses for this injectable three-peptide combination.
Reported / investigational uses
- It is promoted for skin appearance, hair, collagen, inflammation or tissue repair, but claims for an injected blend are not supported by robust human trials.
- Evidence from topical copper-peptide products or laboratory studies cannot establish the safety or effectiveness of this injection.
How it works
GHK-Cu binds copper and has been studied for effects on extracellular-matrix and repair signalling. BPC-157 and thymosin-related peptides have proposed effects on cell migration, blood-vessel signalling and tissue response.
How these substances interact after injection, and whether proposed cellular effects translate into clinical benefit, is unknown.
Potential benefits / effects
- No clinically established skin, hair, anti-ageing or recovery benefit has been shown for this exact injectable formulation.
- Changes in collagen markers or laboratory models do not prove visible, durable or safe results in people.
Potential benefit is not a guarantee of benefit for any individual.
Risks & warnings
- The systemic and long-term risks of the combination are unknown.
- Potential concerns include immune reactions, copper-related effects, injection infection, contamination, incorrect concentration and unpredictable effects on blood-vessel or tissue-growth pathways.
- An attractive cosmetic claim does not reduce the risks of an unverified injectable product.
Possible side effects
Frequency not established
- No reliable common-side-effect rates exist for this exact blend.
- Local pain, redness, swelling, bruising, infection, headache, nausea, flushing or allergic reactions are possible.
Serious or urgent concerns
- Breathing difficulty, facial swelling, high fever, severe pain, spreading redness or other systemic symptoms require urgent assessment.
- Unknown delayed adverse effects remain possible.
Who should not use it / precautions
- The product should not be used outside an authorised research setting.
- Pregnancy, breastfeeding, childhood, active or previous cancer, copper-metabolism disorders, immune disease, bleeding disorders, planned surgery and serious liver or kidney disease increase concern.
- Competitive athletes should note that BPC-157 and TB-500 are relevant to anti-doping prohibitions.
Interactions
- No reliable interaction studies exist for the three-peptide combination.
- Interactions with anticoagulants, immune-modifying drugs, cancer treatments, copper-containing products or other peptides are unknown.
- Unknown does not mean no interaction; a clinician should review all medicines and supplements.
Regulatory / legal status
- The exact injectable blend has no verified UK marketing authorisation and must not be described as approved or clinically validated.
- BPC-157 and thymosin-beta-4 derivatives such as TB-500 are also addressed by anti-doping rules.
Monitoring / professional supervision
- There is no validated monitoring plan that can make unsupervised injection of this blend safe.
- A legitimate study would require authenticated ingredients, sterility testing, eligibility screening, protocol-defined laboratory and clinical checks and adverse-event reporting.
- Cosmetic photographs or subjective improvement are not adequate safety monitoring.
Evidence & sources
Sources are selected for regulatory status, recognised uses and material safety information. They do not validate the HELIX-labelled presentation.
- World Anti-Doping Agency — Prohibited List
- US FDA — Bulk substances that may present compounding safety risks
- PubMed — Review of GHK-Cu biology and preclinical evidence
- ClinicalTrials.gov — BPC-157 study record NCT02637284
Sources accessed and content reviewed 12 September 2026. Regulatory status can change; consult the current official record.
Information disclaimer
HELIX — FOR INFORMATION ONLY. NOT FOR SALE.
The products displayed on this website are presented strictly for informational and educational purposes, helping visitors understand their descriptions, features and specifications. No products are offered for sale through this website, and no product orders or payments are accepted through this platform.
The information on this website does not constitute medical advice, a prescription or a recommendation to use any product. Displaying a product does not establish its regulatory approval, safety or suitability for an individual. Please consult an appropriately qualified healthcare professional for personal medical advice.
For a UK-facing website, this disclaimer does not by itself establish legal compliance. Public advertising of prescription-only medicines and advertising of unlicensed medicines are subject to legal restrictions; the catalogue, wording and presentation require appropriate regulatory review.
Licensed-provider information
Where permitted by applicable law, HELIX may display contact details for independent third-party providers whose registration details have been checked against an appropriate official register. Visitors may contact a listed provider directly to enquire about lawful availability and eligibility requirements.
Any supply is subject to the provider’s assessment, applicable regulations, and verification of all required documentation, which may include a valid prescription, professional licence, identification or other authorisation. A referral does not guarantee availability, eligibility or supply.
Registration status can change. Review the provider's regulator, registration number, official-register record and last-checked date, then verify the current status independently before engaging.